Anzeige
Mehr »
Freitag, 21.11.2025 - Börsentäglich über 12.000 News
Europa im Fokus: Die Lage spitzt sich zu - und ein Player profitiert
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JPMY | ISIN: US64131A1051 | Ticker-Symbol: NRC
Tradegate
20.11.25 | 15:08
1,312 Euro
+16,73 % +0,188
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
NEURONETICS INC Chart 1 Jahr
5-Tage-Chart
NEURONETICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,1201,14020.11.
1,1181,13020.11.

Aktuelle News zur NEURONETICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.11.Neuronetics: TRICARE West Expands NeuroStar TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression3
04.11.Neuronetics targets $40M-$43M Q4 revenue as SPRAVATO mix drives full-year outlook4
04.11.Neuronetics Stock Rises 7% Despite Wider-Than-Expected Q3 Loss2
04.11.Neuronetics reports 11% revenue growth in Q3, CEO to retire in 20263
04.11.Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan171Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of...
► Artikel lesen
04.11.Neuronetics, Inc. - 10-Q, Quarterly Report-
04.11.Neuronetics, Inc. - 8-K, Current Report-
31.10.Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2
NEURONETICS Aktie jetzt für 0€ handeln
30.10.Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence103MALVERN, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
► Artikel lesen
17.09.Neuronetics: New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar Advanced Therapy, to Treat Major Depressive Disorder (MDD)12
06.08.Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)205MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
► Artikel lesen
06.08.Canaccord Genuity lowers Neuronetics stock price target on margin concerns6
05.08.Neuronetics adjusts 2025 gross margin guidance to 48%-50% as Greenbrook revenue mix rises4
05.08.Neuronetics, Inc. Q2 Sales Increase1
05.08.Neuronetics Q2 2025 slides reveal strong revenue growth, path to profitability1
05.08.Neuronetics: EPS verfehlt Schätzungen um 0,07 $ - Umsatz besser als erwartet2
05.08.Neuronetics, Inc. - 10-Q, Quarterly Report1
05.08.Neuronetics Reports Second Quarter 2025 Financial and Operating Results389Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used...
► Artikel lesen
05.08.Neuronetics, Inc. - 8-K, Current Report-
30.07.Neuronetics: NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents1
Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1